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RESUM: 
L’expansió amb albúmina disminueix la incidència d’insuficiència renal i la mortalitat 
dels pacients cirròtics amb peritonitis bacteriana espontània (PBE). Però no està ben 
establert si caldria administrar-la a tots aquests pacients. Aquest estudi determina la 
incidència i evolució de la insuficiència renal i mortalitat en una sèrie no seleccionada 
de pacients cirròtics amb PBE i baix risc de mortalitat (urea<11mmol/l i 
bilirrubina<68µmol/l) no tractats amb albúmina.  
La baixa mortalitat i la bona evolució de la funció renal observades en els pacients 
amb PBE i baix risc de mortalitat no tractats amb albúmina, suggereixen que en 
aquests pacients no caldria administrar albúmina.  
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SUMMARY: 
Albumin infusion has been shown to decrease the incidence of renal impairment and 
mortality in cirrhotic patients with spontaneous bacterial peritonitis (SBP). However, it is 
not well established if albumin should be administered to all SBP patients. This study 
determined the incidence and outcome of renal failure and mortality in a non-selected 
series of cirrhotic patients with SBP and low risk of mortality (urea<11mmol/l and 
bilirubin<68µmol/l) non-treated with albumin. 
The low mortality rates and the favourable outcome of renal function observed in 
patients with SBP and low risk of mortality non-treated with albumin, suggest that 
albumin administration does not seem to be necessary in this setting. 
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1. Abstract 
Background: Intravenous albumin infusion has been shown to decrease the 
incidence of renal impairment and mortality in cirrhotic patients with spontaneous 
bacterial peritonitis (SBP). However, it is not well established if albumin should be 
administered to all patients with SBP or only to those at high risk of mortality. 
Aim: To determine the incidence of renal failure and mortality in a non-selected 
series of cirrhotic patients with SBP and low risk of mortality non-treated with 
albumin. 
Methods: All cirrhotic patients with SBP diagnosed between 2001 and 2007 were 
analyzed. We considered patients al low risk of mortality when urea levels were 
lower than 11 mmol/l and bilirubin levels were lower than 68 µmol/l. We defined 
renal failure when creatinine levels were higher than 133 µmol/l. We determined in-
hospital mortality, mortality at 3 months follow-up, and the incidence and outcome 
of renal failure at diagnosis of SBP and before SBP resolution.  
Results: We included 230 SBP episodes in 180 patients, of these we excluded 14 
patients. Finally we included 216 SBP episodes in 166 patients. Of these 64 
patients (29.6%) were at the low risk of mortality group non-treated with albumin. 
And 152 patients (69%) were at the high risk of mortality group. Of these 73 (48%) 
were treated with albumin and 79 (52%) were not treated with albumin. Renal 
failure at SBP diagnosis, before SBP resolution and the in-hospital mortality and 3 
months mortality in the low risk group compared to the high risk of mortality group 
were 0% vs 40.8% (p< 0.0001), 4.7% vs 25.5% (p= 0.001), 3.1% (2/64) vs 38.1% 
(58/152) (p< 0.0001) and 6.25% (4/64) vs 43.4% (66/152) (p< 0.0001). 
Conclusions: The low mortality rates and the favourable outcome of renal function 
observed in patients with SBP and low risk of mortality non-treated with albumin, 
suggest that albumin administration does not seem to be necessary in this setting. 
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2. Introduction 
Spontaneous bacterial peritonitis (SBP) is a common and severe complication that 
occurs in 10-30% of patients with cirrhosis and ascites(1). Despite the infection 
resolution, the in-hospital mortality is still 20-30%(1).  
One third of patients with SBP develop renal impairment despite successful treatment 
of infection. Renal failure is the most important predictor of in-hospital mortality in 
cirrhotic patients with SBP(2). Furthermore, SBP precipitates hemodynamic 
deterioration, hepatic encephalopathy, gastrointestinal hemorrhage and hepatorenal 
syndrome. 
Sort et al. demonstrated that intravenous albumin infusion given together with antibiotic 
therapy significantly decreased the incidence of renal impairment from 33% to 10% and 
also decreased mortality from 29% to 10%(3) in cirrhotic patients with SBP. In the same 
study it was observed that patients at low risk of mortality (urea < 11mmol/l, bilirubin < 
68 µmol/l) did not benefit from albumin administration because the mortality was 0% in 
the patients treated and non-treated with albumin. 
Moreover, albumin administration is not devoid of side effects and it is expensive. Two 
subsequent studies have therefore tried to identify which subgroup of cirrhotic patients 
with SBP would most benefit from albumin administration(4,5). These two studies 
suggested that patients with a serum bilirubin lower than 68.4 µmol/l and creatinine 
lower than 88.4 µmol/l could be safety treated without albumin because they had a very 
low probability of death or renal failure (4, 5). 
On the other hand, these previous studies included selected series of patients with 
SBP that do not necessarily reflect what happens in the daily clinical practice.  
The objective of our study was to determine the incidence of renal failure and mortality 
in a non-selected series of cirrhotic patients with SBP and low risk of mortality not-
treated with albumin. 
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3. Methods 
3.1. Patients population 
We reviewed all SBP episodes diagnosed in cirrhotic patients in Hospital de la Santa 
Creu i Sant Pau during the period between January 2001 and December 2007.  We 
identified SBP episodes by reviewing in the Biochemistry Laboratory. Patients were 
considered at low risk of mortality(3) when urea was less than 11 mmol/l (BUN 30 mg/dl) 
and bilirubin less than 68 µmol/l (4mg/dl). In contrast patients were considered at high 
risk of mortality when urea was higher than or equal to 11 mmol/l and/or bilirubin higher 
than or equal to 68 µmol/l.  
The diagnosis of cirrhosis was based on clinical, biochemical, endoscopic and 
ultrasonographical findings with or without liver biopsy. Diagnosis of SBP was based on 
the presence of polymorphonuclear cells in ascitic fluid with a cell count higher or equal 
than 250 cells/mm3 in the absence of findings suggestive of secondary peritonitis(6) or 
peritoneal carcinomatosis. Pathogen isolation was not considered essential for SBP 
diagnosis. The exclusion criteria were: hemodialysis, terminal illness, being transfered 
to another hospital, low risk SBP treated with albumin and low risk SBP with renal 
failure (creatinine > 133 µmol/l) at SBP diagnosis(7). We have excluded patients with 
creatinine > 133 µmol/l because these patients should receive albumin in order to treat 
the hepatorenal syndrome that has already been established and are not therefore 
candidates to renal failure prevention. 
 
3.2. Treatment and assessments 
Microbiological study of ascitic fluid was performed by bedside inoculation into two 
blood culture bottles (aerobic and anaerobic, 10 ml each), when possible, in view of the 
quantity of ascitic fluid obtained at paracentesis(8,9). Renal failure was considered when 
serum creatinine values were above 133 mmol/l (1.5mg /dl)(2,3). Septic shock was 
defined as a decrease in systolic blood pressure below 90 mm Hg or a reduction of 
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more than 40 mm Hg from baseline, despite adequate fluid resuscitation, accompanied 
by tachycardia and oliguria (urine output less than 20 ml/h) or anuria in the absence of 
other causes of shock(10). Resolution of SBP was considered when signs and 
symptoms of infection had disappeared, ascitic fluid neutrophil count was <250/mm3, 
and ascitic fluid culture was negative (11). 
Patients were initially empirically treated with intravenous ceftriaxone 2 g daily for 7 
days or until the infection was resolved. The antibiotic therapy was modified  
empirically or according to the in vitro susceptibility of causative microorganisms when 
there was an unfavourable clinical and/or analytical evolution of the infection.  
Diuretic treatment was discontinued at the time of SBP diagnosis and it was not 
allowed until infection resolution. 
All patients at low risk of mortality group were treated only with antibiotic while among 
the high risk of mortality group, patients received albumin infusion or not according to 
the medical team taking care of the patient. 
Albumin was given at a dose of 1.5 g per kilogram of body weight during the first day 
after diagnosis, followed by 1 g per kilogram on the third day. 
The main endpoints of the study were mortality and the development of renal failure. 
 
3.3.  Statistical analysis 
Comparisons between groups were performed with the chi-square test or Fisher’s 
exact test for qualitative variables and Student’s t-test for quantitative variables. 
Probability of survival was calculated and compared by Kaplan-Meier with log rank test. 
Variables that reached statistical significance in univariate analyses were included in a 
multivariate analyses by logistic regression to identify the independent predictive 
factors of in-hospital mortality. A forward procedure with Wald test was used to 
determine the best model. Calibration was assessed using the Hosmer-Lemeshow 
goodness-of-fit test. Results are presented as means ± standard deviation or 
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frequencies. Calculations were performed with the SPSS Statistical Package (version 
17.0, 2006; SPSS Inc., Chicago, IL). A p value <0.05 was considered statistically 
significant. 
 
4. Results 
4.1. Patients population 
Two hundred and thirty SBP episodes in 180 cirrhotic patients were diagnosed in 
Hospital de la Santa Creu i Sant Pau during the period between January 2001 and 
December 2007.   
We only excluded 14 patients, for the following reasons: hemodialysis (3), terminal 
illness (1 terminal HIV infection, 1 terminal hepatocellular carcinoma), transferred to 
another hospital (1), low risk SBP treated with albumin (4) and low risk SBP with renal 
failure (creatinine > 133 µmol/l) at SBP diagnosis (4) (7). Therefore, we finally evaluated 
216 SBP episodes in 165 patients of whom 64 (29.6%) were considered at low risk of 
mortality and none of them was treated with albumin. In contrast, 152 (70.4%) were 
considered at high risk of mortality, of these 73 (48%) were treated with albumin and 79 
(52%) were not treated with albumin, according to the criteria of the medical team 
taking care of the patients. 
 
4.2. Base-line patients characteristics 
When comparing clinical and laboratory characteristics (see table 1), the low risk of 
mortality patients showed a lower Child Pugh and MELD scores and a lower urea, 
creatinine, bilirubin, INR and blood leukocyte count than patients at high risk.  
Moreover, they showed a higher sodium and mean arterial pressure than the high risk 
of mortality patients.  
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Table 1. Basal characteristics of high risk and low risk of mortality patients. 
 Low risk 
(n=64) 
High risk 
(n=152) 
p 
Age (years) 63.5 ± 13.8 63.0 ± 12.8 0.803 
Sex                  Male 
Female 
42 (65.6%) 
22 (34.4%) 
105 (69.1%) 
47 (30.9%) 
0.619 
Etiology  
     
Alcohol 
HCV 
Other 
17 (26.6%) 
33 (51.6%) 
14 (21.9%) 
67 (44%) 
52 (34.2%) 
33 (21.7%) 
0.030 
Hepatocellular carcinoma 18 (28.1%) 39 (25.6%) 0.730 
Previous SBP 
Encephalopathy  
Ascites  
GI bleeding  
11 (17.2%) 
16 (25%) 
45 (70.3%) 
17 (26.6%) 
37 (24.3%) 
44 (28.9%) 
115 (75.6%) 
39 (25.6%) 
0.248 
0.554 
0.413 
0.911 
Child-Pugh 
MELD 
MELD-Na 
8.8 ± 1.7 
13.2 ± 3.0 
16.4 ± 3.7 
9.7 ± 1.6 
21.4±6.5 
25.0±6.1 
< 0.0001 
< 0.0001 
< 0.0001 
HIV infection 6 (9.4%) 11 (7.2%) 0.594 
Previous norfloxacin 11 (17.2%) 44 (28.9%) 0.070 
Nosocomial SBP 23 (35.9%) 50 (32.9%) 0.666 
Departament Hepatology 
Others 
52 (81.2%) 
12 (18.7%) 
125 (82.2%) 
27 (17.8%) 
0.863 
Fever 27 (42.2%) 53 (34.9%) 0.309 
Abdominal pain 26 (40.6%) 59 (38.8%) 0.804 
Ileus 0 (0%) 3 (1.9%) 0.557 
Shock 2 (3.1%) 10 (6.6%) 0.516 
Encephalopathy 14 (21.9%) 52 (34.2%) 0.072 
Gastrointestinal bleeding (GI) 3 (4.7%) 18 (11.8%) 0.105 
Sodium (mmol/l) 135.5 ± 4.4 131.9 ± 5.9 < 0.0001 
Potassi (mmol/l) 4.2 ± 0.6 4.6 ± 0.8 < 0.0001 
Urea (mmol/l) 6.6 ± 2.5 14.6 ± 7.1 < 0.0001 
Creatinine (µmol/l) 85.5 ± 18.5 139.3 ± 73.5 < 0.0001 
Bilirubin (µmol/l) 37.9 ± 18.0 119.1 ± 127.8 < 0.0001 
INR 1.39 ± 0.21 1.74 ± 0.59 < 0.0001 
Blood leukocyte count (x 109/l) 7.93 ± 4.6 11.44 ± 9.2 < 0.0001 
Mean arterial pressure (mmHg) 86.4 ± 14.2 75.9 ± 14.9 < 0.0001 
Ascites neutrophil count (/mm3) 3494 ± 5821 4159 ± 8225 0.558 
Ascitic fluid total protein (g/l) 13.4 ± 8.1 13.3 ± 6.9 0.978 
Positive ascitic fluid culture  19 (29.7%) 70 (46%) 0.026 
 
When comparing high risk patients treated to non-treated with albumin (see table 2), 
the treated ones showed a higher MELD score and serum bilirubin levels. It was found 
that albumin was less frequently indicated in patients from other departments apart 
from the hepatology unit and also in patients with gastrointestinal bleeding.  
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Table 2. Basal characteristics of high risk of mortality patients treated with albumin and 
non-treated with albumin.  
 
 
 High risk of 
mortality non-
treated with 
albumin     
(n=79) 
High risk of 
mortality 
treated with 
albumin 
 (n=73) 
p 
Age (years) 63.6 ± 13.5 62.4 ± 12.2 0.555 
Sex                        Male 
Female 
59 (74.7%) 
20 (25.3%) 
46 (63%) 
27 (37%) 
0.120 
Etiology        Alcohol 
HCV 
Others 
36 (45.6%) 
23 (29.1%) 
20 (25.3%) 
31 (42.5%) 
29 (39.7%) 
13 (17.8%) 
0.314  
Hepatocellular carcinoma 19 (24%) 20 (27.3%) 0.620 
Previous SBP 
Encephalopathy  
Ascites  
GI bleeding 
19 (24%) 
25 (31.6%) 
60 (75.9%) 
20 (25.3%) 
18 (24.6%) 
19 (26%) 
55 (75.3%) 
19 (26%) 
0.931 
0.445 
0.931 
0.880 
Child-Pugh 
MELD 
MELD-Na 
9.7 ± 1.5 
20.3 ± 6.5 
24.1 ± 6.4 
9.9 ± 1.7 
22.6 ± 6.4 
26.0 ± 5.8 
0.555 
0.030 
0.059 
HIV infection 8 (10.1%) 3 (4.1%) 0.153 
Previous norfloxacin 22 (27.8%) 22 (30.1%) 0.756 
Nosocomial SBP 30 (37.9%) 20 (27.4%) 0.166 
Departament Hepatology 
Others 
59 (74.7%) 
20 (25.3%) 
66 (90.4%) 
7 (9.6%) 
0.011 
Fever 32 (40.5%)  21 (28.8%) 0.129 
Abdominal pain 25 (31.6%) 34 (46.6%) 0.059 
Ileus 1 (1.3%) 2 (2.7%) 0.514 
Shock 7 (8.9%) 3 (4.1%) 0.331 
Encephalopathy 27 (34.2%) 25 (34.2%) 0.993 
Gastrointestinal  bleeding (GI) 14 (17.7%) 4 (5.5%) 0.02 
Sodium (mmol/l) 132.1 ± 6.5 131.7 ± 5.3 0.696 
Potassi (mmol/l) 4.7 ± 0.76 4.59 ± 0.93 0.413 
Urea (mmol/l) 14.4 ± 6.3 14.8 ± 7.9 0.770 
Creatinine (µmol/l) 138.7 ± 68.4 139.9 ± 79.1 0.914 
Bilirubin (µmol/l) 96.6 ± 102.7 143.2 ± 147.0 0.027 
INR 1.7 ± 0.7 1.8 ± 0.5 0.265 
Blood leukocyte count (x 109/l) 10.59 ± 7.87 12.36 ± 10.48 0.239 
Mean arterial pressure (mmHg) 74.7 ± 15.8 77.3 ± 13.7 0.295 
Ascites neutrophil count (/mm3) 3462 ± 4809 4904 ± 10729 0.283 
Ascitic fluid total protein (g/l) 13.1 ± 7.1 13.6 ±6.7 0.649 
Positive ascitic fluid culture  38 (48.1%) 31 (42.5%) 0.311 
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4.3.  Renal failure 
Data concerning renal failure are shown in figure 1. There were no statistical 
differences in previous renal failure between groups (we only had the data available in 
188 episodes). Renal failure at SBP diagnosis was found in 112/216 (51.8%) SBP 
episodes: 0/64 patients in the low risk group and 62/152 (40.8%) in the high risk of 
mortality group (p< 0.001). When considering only patients at high risk of mortality we 
did not find statistical differences in this parameter between patients treated or not with 
albumin: 30/73 (41%) of the patients who were treated with albumin and 32/79 (40.5%) 
of the patients who were not treated with albumin presented with renal failure at SBP 
diagnosis (p= 0.94). 
Renal failure before SBP resolution was found in 26/154 (16.8%): 3/64 (4.7%) patients 
in the low risk group and 23/90 (25.5%) patients in the high risk group (p=0.001). The 
patients from the low risk of mortality group who developed renal failure before SBP 
resolution had a favourable outcome although they were not treated with albumin: renal 
failure resolved in all of the patients and non of them needed to be treated with 
terlipressin and albumin.  
There was a trend to a lower incidence of renal failure before SBP resolution among 
high risk patients treated than not treated with albumin (8/43, 18.6% against 15/47, 
32%, p= 0.14,  respectively).  
In the low risk group 58/64 (90.6%) patients were discharged with normal renal 
function, compared to 71/152 (50.6%) in the high risk group (p< 0.0001). Among  high 
risk patients it was higher in patients treated (43/73, 59%) than non-treated with 
albumin (34/79, 43%) (p=0.051). 
The four patients in the low risk of mortality group who were discharged with impaired 
renal function, it was developed after the SBP was resolved. 
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Figure 1. Previous renal failure, renal failure ay SBP diagnosis and before SBP 
resolution and patients discharged with normal renal function in the whole series. 
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4.4. Mortality 
Mortality during hospitalization was significantly lower among low risk patients than in 
high risk patients (3.1% versus 38.1%, p< 0.001). The causes of death in the two 
patients who died in the low risk group were multiorgan failure in advanced HIV 
infection and advanced hepatocellular carcinoma. Considering high risk patients, in-
hospital mortality was lower in those receiving albumin than in those not receiving it 
(29% versus 47%, p=0.02). 
In addition, the probability of 3-month survival was statistically higher in the low risk 
than in the high risk patients (93% versus 55%, p< 0.001). The causes of death in the 
two low risk of mortality patients at 3 months were advanced hepatocellular carcinoma 
and myocardial infarction. There was a higher probability of 3-month survival in high 
risk patients treated than non treated with albumin (62% versus 48%, p=0.02). (Figure 
2). 
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Figure 2. Probability of survival. 
Low risk
High risk albumin
High risk
High risk no albumin
93%
63%
55%
48%
p<0.001
p=0.02
Period (days)
S
u
rv
iv
al
 
 
Considering the whole series, the independent predictive factors of in-hospital mortality 
were urea, blood leukocyte count, mean arterial pressure, MELD score and nosocomial 
SBP. Considering only the high risk patients, the independent predictive factors of 
mortality were urea, blood leukocyte count, mean arterial pressure, MELD score and 
not being treated with albumin (tables 3 and 4). 
 
Table 3. Independent predictive factors of in-hospital mortality in the whole series. 
 OR CI 95% p 
Urea (mmol/l) 1.117 1.049-1.189 0.001 
Blood leukocyte count (x 109/l) 1.054 1.006-1.104 0.02 
Mean arterial pressure (mmHg) 0.965 0.936-0.994 0.02 
MELD 1.123 1.053-1.197 <0.001 
Nosocomial SBP 2.70 1.16-6.25 0.02 
 
Table 4. Independent predictive factors of in-hospital mortality in the high risk of 
mortality patients. 
 OR CI 95% p 
Urea (mmol/l) 1.117 1.046-1.192 0.001 
Blood leukocyte count (x109/l) 1.058 1.009-1.109 0.02 
Mean arterial pressure (mmHg) 0.965 0.934-0.998 0.04 
MELD 1.132 1.052-1.217 0.001 
No treated with albumin 4.83 1.87-12.45 0.001 
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5. Discussion  
The main finding of the present retrospective study is the low mortality and incidence of 
renal failure in cirrhotic patients with SBP and low risk of mortality non-treated with 
albumin.  
Sort et al demonstrated that albumin administration reduced the incidence of renal 
impairment and mortality in selected patients with SBP. However, albumin 
administration is not devoid of side effects and is expensive. After one study failed to 
find an alternative to albumin in hydroxyethyl starch (12), it has been questioned if all 
SBP patients need albumin treatment.  
In two previous studies, Terg et al and Sigal et al showed that patients with SBP and 
creatinine lower than 88.4 µmol/l and bilirubin lower than 68.4 µmol/l could be treated 
without albumin because they had very low likelihood of death or renal failure. These 
two studies used creatinine and bilirubin levels to classify patients because these were 
the independent predictive factors of renal impairment in the study of Sort et al. In our 
study, we decided to classify patients as high or low risk of mortality according to urea 
and bilirubin levels which were the independent predictive factors of in-hospital 
mortality in the same study. 
It should be pointed out that previous studies excluded a high number of patients in 
order to analyze a group as homogeneous as possible (3, 4). We wanted however to 
assess a group of patients as similar as possible to the daily clinical practice, and we 
therefore analyzed this non-selected series. In spite of this, patients at low risk of 
mortality not treated with albumin showed a low in-hospital mortality (3%) and 3-month 
probability of mortality (6%), these figures being significantly lower than in patients at 
high risk of mortality. In addition, the causes of death in low risk patients were mostly 
not related to cirrhosis and SBP (multiorgan failure in HIV patient and advanced 
hepatocellular carcinoma). Low risk of mortality patients showed not only a low 
incidence of renal failure, but also most patients developing this complication presented 
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a favourable outcome. Our results therefore confirm those from the study of Sort et al, 
in which selected patients with SBP and urea < 11 mmol/l and bilirubin < 68 µmol/l did 
not show in-hospital mortality, independently of having been treated with albumin or not 
at SBP diagnosis.  
Multivariate analysis in our whole series showed that in-hospital mortality was 
associated with worse liver and renal function (MELD, urea), more severe sepsis 
(blood leukocyte count) and hemodynamic impairment (mean arterial pressure), and 
with nosocomial SBP acquisition. This is in agreement with previous studies and  point 
out the importance of urea in the prognosis of SBP.        
In spite of patients at high risk of mortality treated with albumin presented a worse liver 
function compared to those at high risk non-treated with albumin, they showed a  better 
outcome in terms of renal failure and mortality.  Moreover, absence of albumin 
treatment was a strong independent predictive factor of in-hospital mortality in the 
multivariate analysis including only patients at high risk of mortality.  These data 
strongly supports the need for albumin expansion in high risk of mortality patients. 
Our study has several limitations, such as the retrospective design and that albumin 
administration was not decided by randomization in high risk of mortality patients. In 
spite of this, we think that this study provides valuable clinical information. We conclude 
that patients with SBP and low risk of mortality could be safely treated without albumin 
as they have a very low probability of mortality and renal failure. In contrast, our data 
suggest that patients with SBP and high risk of mortality clearly benefit from albumin 
administration.   
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6. Conclusions 
· We confirm that serum bilirubin and urea are useful parameters to identify 
cirrhotic patients with SBP at high and low risk of mortality.  
· Although it is not a randomized study, our data support that albumin 
administration improves survival and renal function in cirrhotic patients with 
SBP and high risk of mortality. 
· The low mortality rates and the favourable outcome of renal function 
observed in cirrhotic patients with SBP and low risk of mortality non-treated 
with albumin, suggest that albumin administration does not seem to be 
necessary is this setting. 
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